HemoBioTech (OTCBB: HMBT), was recently highlighted in an article that appeared in the December 5, 2007 edition of the Flaherty Financial News, Inc. Newsletter. The piece examined the company's continued development of HemoTech and its ongoing continued corporate strategy. To read the article, visit the following link: http://archive.constantcontact.com/fs070/1101855435216/archive/1101901 066018.html. (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
Titled, "Consider the Possibilities in HMBT Stock and the Potential of HemoBioTech's Artificial Blood, HemoTech," the newsletter article addresses the worldwide blood shortage and HemoBioTech's quest to develop and deliver the first viable blood substitute. "The search for artificial human blood is like the quest for the Holy Grail," author Bob Flaherty writes. "After decades of striving and failing, new corporate knights keep trying to achieve something that would save so many lives, not only on the battle fields and after accidents, but in numerous daily medical procedures. Leading this new quest for this particular Holy Grail is Dr. Arthur Bollon, scientist and entrepreneur."
The Flaherty Financial News, Inc. piece also notes the company's strategy and next steps including the goal of launching clinical trials in India, a potential stand-alone $1 billion annual market, and the goal of initiating U.S. clinical trials shortly thereafter.
"I am gratified that Bob Flaherty featured HemoBioTech in his newsletter," said Arthur Bollon, PhD, Chairman and CEO of HemoBioTech. "We believe the unique chemical modification of hemoglobin in HemoTech developed by Dr. Jan Simoni and Dr. Mario Feola, provides the structural mechanism necessary to nullify the toxicity issues that have plagued other companies' attempts."
About Flaherty Financial News
Flaherty Financial News (FFN) is the publisher of totally-electronic coverage of the neglected micro and small- cap markets. It was recently launched by the "legendary financial editor" Bob Flaherty, Editor and Chairman of Flaherty Financial News Inc, together with his son Brian, who serves as President and Publisher. While previously serving as Chairman and Editor of Equities Magazine for twenty-five years until it was sold in September 2006, Bob was also Editor-in-Chief of Equities Special Situations, which had one of the most consistent and highest ranked long-run records measured by Hulbert Financial Digest. Previously, he was an award-winning Senior Editor at Forbes Magazine, where he wrote 33 cover stories, two shy of the all time record. He was also Chairman of The Over-The-Counter Securities Fund. Bob Flaherty is a Magna Cum Laude graduate of Harvard College in economics and also has an MBA with a Distinction in Finance from Harvard Business School.
About HemoBioTech, Inc.
HemoBioTech is working on the development and commercialization of HemoTech, a novel human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center. HemoTech is composed of bovine hemoglobin that is chemically modified with adenosine triphosphate, adenosine, and glutathione. In addition to carrying oxygen through the bloodstream, HemoTech also induces erythropoiesis (red blood cell production). Based on preclinical studies and an initial foreign human clinical study, the company believes that HemoTech, due to its novel chemical composition, may significantly diminish or even eliminate the intrinsic toxicities that have plagued other attempts at developing blood substitutes. HemoTech is currently undergoing additional studies to confirm and possibly expand on these results. HemoTech is being developed to help reduce or eliminate the danger resulting from acute blood loss in trauma, surgery, and other conditions. Corporate headquarters are located at 5001 Spring Valley Road, Suite 1040-West, Dallas, Texas 75244. For further information visit our website at http://www.hemobiotech.com.
Safe Harbor Statement
Except for historical information, the matters discussed in this news release may be considered "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief, or current expectations of HemoBioTech and its management and are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others the successful pre-clinical development, the successful completion of clinical trials, the FDA review process and other governmental regulation, pharmaceutical collaborator interest and ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors which are included in HemoBioTech's Annual Report on Form 10-KSB for the year ended December 31, 2006, as amended, and HemoBioTech's other reports filed with the Securities and Exchange Commission.
